283 related articles for article (PubMed ID: 28128200)
21. WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation.
Jeong WJ; Park JC; Kim WS; Ro EJ; Jeon SH; Lee SK; Park YN; Min DS; Choi KY
Nat Commun; 2019 Jan; 10(1):295. PubMed ID: 30655611
[TBL] [Abstract][Full Text] [Related]
22. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous knockdown of multiple ligands of innate receptor NKG2D prevents natural killer cell-mediated fulminant hepatitis in mice.
Huang M; Sun R; Wei H; Tian Z
Hepatology; 2013 Jan; 57(1):277-88. PubMed ID: 22806577
[TBL] [Abstract][Full Text] [Related]
24. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
Mincheva-Nilsson L; Baranov V
Semin Cancer Biol; 2014 Oct; 28():24-30. PubMed ID: 24602822
[TBL] [Abstract][Full Text] [Related]
25. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
26. The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies.
Ruck T; Bittner S; Afzali AM; Göbel K; Glumm S; Kraft P; Sommer C; Kleinschnitz C; Preuße C; Stenzel W; Wiendl H; Meuth SG
Oncotarget; 2015 Dec; 6(41):43230-43. PubMed ID: 26646698
[TBL] [Abstract][Full Text] [Related]
27. The expression and function of NKG2D molecule on intrahepatic CD8+ T cells in chronic viral hepatitis.
Kennedy PT; Gehring AJ; Nowbath A; Selden C; Quaglia A; Dhillon A; Dusheiko G; Bertoletti A
J Viral Hepat; 2008 Dec; 15(12):901-9. PubMed ID: 19087227
[TBL] [Abstract][Full Text] [Related]
28. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of Hepatocellular Carcinoma.
Heinrich B; Czauderna C; Marquardt JU
Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
[TBL] [Abstract][Full Text] [Related]
30. NKG2D: A versatile player in the immune system.
Jelenčić V; Lenartić M; Wensveen FM; Polić B
Immunol Lett; 2017 Sep; 189():48-53. PubMed ID: 28414183
[TBL] [Abstract][Full Text] [Related]
31. NKG2D and its ligands.
Obeidy P; Sharland AF
Int J Biochem Cell Biol; 2009 Dec; 41(12):2364-7. PubMed ID: 19631280
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the antitumor activity of platinum nanoparticles in the treatment of hepatocellular carcinoma induced in rats.
Medhat A; Mansour S; El-Sonbaty S; Kandil E; Mahmoud M
Tumour Biol; 2017 Jul; 39(7):1010428317717259. PubMed ID: 28720064
[TBL] [Abstract][Full Text] [Related]
33. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.
O'Rourke JM; Sagar VM; Shah T; Shetty S
World J Gastroenterol; 2018 Oct; 24(39):4436-4447. PubMed ID: 30357021
[TBL] [Abstract][Full Text] [Related]
34. Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma.
Abdelrahman MM; Fawzy IO; Bassiouni AA; Gomaa AI; Esmat G; Waked I; Abdelaziz AI
Hum Immunol; 2016 Aug; 77(8):667-673. PubMed ID: 27262453
[TBL] [Abstract][Full Text] [Related]
35. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
36. Metabolome Analyses Uncovered a Novel Inhibitory Effect of Acyclic Retinoid on Aberrant Lipogenesis in a Mouse Diethylnitrosamine-Induced Hepatic Tumorigenesis Model.
Qin XY; Tatsukawa H; Hitomi K; Shirakami Y; Ishibashi N; Shimizu M; Moriwaki H; Kojima S
Cancer Prev Res (Phila); 2016 Mar; 9(3):205-14. PubMed ID: 26744170
[TBL] [Abstract][Full Text] [Related]
37. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8
Hu J; Bernatchez C; Zhang L; Xia X; Kleinerman ES; Hung MC; Hwu P; Li S
Cancer Immunol Res; 2017 Apr; 5(4):300-311. PubMed ID: 28223282
[TBL] [Abstract][Full Text] [Related]
38. β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling.
Yang Y; Guo Y; Tan S; Ke B; Tao J; Liu H; Jiang J; Chen J; Chen G; Wu B
Nat Commun; 2015 Jun; 6():7369. PubMed ID: 26077142
[TBL] [Abstract][Full Text] [Related]
39. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
Shin S; Kim M; Lee SJ; Park KS; Lee CH
Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
[TBL] [Abstract][Full Text] [Related]
40. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
Smyth MJ; Swann J; Kelly JM; Cretney E; Yokoyama WM; Diefenbach A; Sayers TJ; Hayakawa Y
J Exp Med; 2004 Nov; 200(10):1325-35. PubMed ID: 15545356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
